UNSPSC 51434913: Benazepril/hydrochlorothiazide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434913 Benazepril/hydrochlorothiazide is a Commodity code representing a single antihypertensive pharmaceutical product, but state and local procurement activity under this code shows substantial variance from the nominal product specification. Recent solicitations reveal that state and local governments are buying advanced life support medications (epinephrine, adenosine, diltiazem, labetalol), generic multi-source pharmaceuticals through cooperative purchasing alliances, and direct-to-manufacturer prescription fulfillment programs — categories that span emergency medical supplies, broad-spectrum generic drug inventories, and pharmacy benefit program infrastructure rather than a single fixed-combination agent. Issuing bodies include municipalities (City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The Tampa Fire Rescue solicitation targets emergency medical services; the Texas HHS RFI targets state employee and retiree pharmacy benefits; and the MMCAP RFP targets state and local government facilities, health plans, and participating jurisdictions across multiple states.

Geographic activity centers on Texas, Minnesota, and Florida in the most recent opportunities, with MMCAP cooperative membership extending to Oregon and other participating jurisdictions. Recent representative solicitations include the City of Tampa's IFB (Solicitation 26P00188) for Advanced Life Support Medications due April 8, 2026, with an estimated contract value of $40,000 and a one-year term plus renewal options; the Minnesota Department of Administration's RFP through MMCAP (Solicitation S1070000015802) for generic multi-source pharmaceuticals and OTC products due March 26, 2026, with a two-year initial term; and the Texas HHS Commission's RFI (Solicitation HHS0017013) exploring direct-to-manufacturer prescription delivery models, posted April 3, 2026. The Tampa solicitation carries a 5 percent bid discount for Small Local Business Enterprise (SLBE) participation not to exceed $10,000; the MMCAP RFP imposes a 3 percent administrative fee and performance penalties of $200–$1,500 per violation; and all solicitations require FDA compliance, expiration-date warranties, and safety or accessibility documentation per federal and state standards.